Asebio warns that the cuts in the Government plan will have a negative impact on innovation

The industry which represents Asebio needs a framework for action to ensure its stability and encourage innovative activity that characterizes it and that is the basis of its business, aimed at providing solutions to diseases in many currently incurable cases. Innovation is the core of the production model that seeks recovery of Spain and which guarantees the availability of a large number of innovative medicines and diagnostic systems necessary for the prevention and treatment of a multitude of diseases so far without therapeutic solution.

For this reason, this sector lends itself to seek solutions in a way agreed to this situation that inexorably harms all the industrial fabric and researcher biopharmaceutical so important for the development of innovation. The biopharmaceutical market accounts for more than 20% of all r & d carried out in Spain. The development of new molecules involves an important technological and industrial process, which no doubt will be affected by the delay of the projects of the companies.

At the same time, Asebio believes that the most innovative products such as medicines and biotechnology, as for example, monoclonal antibodies, blood, etc., orphans, particularly sensitive to these measures, since that your research requires an additional effort to be suitable for a small group of patients should be excluded from these cuts. The exclusion of these products has been referred to even in health cuts produced in Greece.